http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Gamal M. Hassan(Gamal M. Hassan ) (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Elnemr, Gamal M,El-Rashidy, Ahmed H,Osman, Ahmed H,Issa, Lotfi F,Abbas, Osama A,Al-Zahrani, Abdullah S,El-Seman, Sheriff M,Mohammed, Amrallah A,Hassan, Abdelghani A Asian Pacific Journal of Cancer Prevention 2016 Asian Pacific journal of cancer prevention Vol.17 No.2
Triple-negative breast cancers constitute about 15% of all cases, but despite their higher response to neoadjuvant chemotherapy, the tumors are very aggressive and associated with a poor prognosis as well as a higher risk of early recurrence. This study was retrospectively performed on 101 patients with stage II and III invasive breast cancer who received 6-8 cycles of neo-adjuvant chemotherapy. Out of the total, 23 were in the triple negative breast cancer subgroup. Nuclear Ki-67 expression in both the large cohort group (n=101) and triple negative breast cancer subgroup (n=23) and its relation to the pathological response were evaluated. The purpose of the study was to identify the predictive value of nuclear protein Ki-67 expression among patients with invasive breast cancers, involving the triple negative breast cancer subgroup, treated with neoadjuvant chemotherapy in correlation to the rate of pathological complete response. The proliferation marker Ki-67 expression was highest in the triple negative breast cancer subgroup. No appreciable difference in the rate of Ki-67 expression in triple negative breast cancer subgroup using either a cutoff of 14% or 35%. Triple negative breast cancer subgroup showed lower rates of pathological complete response. Achievement of pathological complete response was significantly correlated with smaller tumor size and higher Ki-67 expression. The majority of triple negative breast cancer cases achieved pathological partial response. The study concluded that Ki-67 is a useful tool to predict chemosensitivity in the setting of neoadjuvant chemotherapy for invasive breast cancer but not for the triple negative breast cancer subgroup.
-
Amal G. Ramadan(Amal G. Ramadan ),Ahmed A. M. Yassein(Ahmed A. M. Yassein ),Eissa A. Eissa(Eissa A. Eissa ),Gamal M. Hassan(Gamal M. Hassan ) 한국축산식품학회 2022 Food and Life Vol.2022 No.3
Zinc oxide nanoparticles (ZnO-NPs) are regularly utilized in the food and fertilizers industries. In our investigation, rats received oral administration of ZnO NPs with a particle size of 30±5 nm once daily at doses of 100, 200, 300, 400, and 600 mg/kg for ten weeks in order to assess the genotoxic effect. Impacts on hematological markers, genotoxic impact, and growth were investigated. The findings showed that ZnO-NPs significantly reduced body weight gain, red blood cell count (RBC), hemoglobin concentration (Hb), hematocrit value (HCT), and platelet count (PLT), while increasing white blood cell (WBC), mean capsular volume (MCV), mean capsular hemoglobin (MCH), and mean capsular hemoglobin concentration (MCHC) in the treated rats. Our results for the comet assay and micronuclei test show a dosage-dependent increase in DNA fragmentation, which was supported by an increase in the percentage of DNA that is tailed, the length and intensity of DNA tails, and the tail moment, especially at the dose of 600 mg/kg. According to the findings, the frequency of micronucleated cells has increased.
-
MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary
Abdelaal, Shereen E,Habib, Fahima M,el Din, Amina A Gamal,Gabal, Samia M,Hassan, Nabila S,Ibrahim, Nihad A Asian Pacific Journal of Cancer Prevention 2016 Asian Pacific journal of cancer prevention Vol.17 No.7
Background: Different types of cancer exhibit abnormalities in cell cycle regulators. The murine double minute-2(MDM2) cell cycle regulator is a proto-oncogene that negatively regulates the P53 tumour suppressor gene. Surface epithelial tumours constitute approximately two thirds of ovarian neoplasms. Each histologic type can be classified as benign, borderline and malignant. This study aimed to examine immunohistochemical expression of the MDM2 protein in ovarian serous and mucinous epithelial tumours (benign, borderline and malignant). Materials and Methods: This study included forty five ovarian tumours, subdivided into fifteen cystadenomas (5 serous and 10 mucinous), fifteen borderline tumours (11 serous and 4 mucinous) and fifteen cystadenocarcinomas (9 serous and 6 mucinous). Paraffin sections were stained with haematoxylin and eosin for histopathologic study, and with mouse monoclonal anti-MDM2 antibody for immunohistochemistry. Results: MDM2 positivity was detected in 28.9% of the studied ovarian tumours. All benign tumours were negative and positivity was significantly higher in malignant than borderline tumours (P value of chi-square test =0.000). Significantly, all MDM2 positive mucinous tumours were malignant with no positive mucinous borderline tumours. Malignant tumours showed positive MDM2 expression in 83.3% of mucinous type and in 55.6% of serous type. Borderline serous tumours showed negative MDM2 in 72.7% of cases (P value of Z test =0.04). Conclusions: Alterations in the expression of the cell cycle regulator (MDM2) occur early in the process of tumourigenesis in serous and mucinous ovarian tumours. We suggest that MDM2 may be used in those tumours as a marker for risk stratification and identification of cases with cancer development and progression. We recommend further studies on MDM2 immunohistochemistry, in conjunction with adjuvant methods as DNA ploidy and FISH gene amplification, focusing on the mucinous tumours and differentiating between the three tumour categories, benign, borderline and malignant.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
